Company Filing History:
Years Active: 2021-2025
Title: Innovator Spotlight: Zhongdong Huang – Pioneering Macrocyclic Compounds for Disease Treatment
Introduction: Zhongdong Huang is a prominent inventor based in San Diego, California. He currently holds five patents, showcasing his contributions to the field of pharmaceutical innovations. His work focuses on developing novel compounds that offer potential solutions in the treatment of various diseases.
Latest Patents: One of Zhongdong Huang's latest patents is titled "Chiral Diaryl Macrocycles and Uses Thereof." This disclosure pertains to specific diaryl macrocycle compounds, particularly (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one. The patent highlights its applications in treating diseases in mammals, primarily focusing on humans. Another significant patent is "Macrocyclic Compounds and Uses Thereof," which relates to macrocyclic compounds that inhibit SRC, MET, and/or CSFR. This patent encompasses pharmaceutical compositions containing these compounds and outlines methods for employing these compounds in cancer treatment.
Career Highlights: Zhongdong Huang is affiliated with Turning Point Therapeutics, Inc., where he continues to drive innovation in the pharmaceutical sector. His expertise in macrocyclic compounds has positioned him as a key contributor to advancements in treatment methodologies. His dedication to research and development has resulted in substantial contributions to the understanding of how these compounds can effectively interact with disease mechanisms.
Collaborations: Throughout his career, Zhongdong Huang has collaborated with esteemed colleagues in the industry. Notable coworkers include Jingrong Jean Cui and Evan W. Rogers, who share a commitment to pushing the boundaries of pharmaceutical research. Together, they work towards translating scientific discoveries into viable therapeutic options.
Conclusion: Zhongdong Huang stands out as an influential inventor in the landscape of pharmaceutical innovations. His patents reflect his deep understanding of macrocyclic compounds and their potential applications in treating diseases. As he continues to collaborate with talented professionals within Turning Point Therapeutics, Inc., his contributions are likely to advance significantly in the coming years, benefitting both the scientific community and patients worldwide.